LGALS9 and neoplasm: In contrast, some inhibitory ICR/ICL pairs such as CD24-SIGLEC10 and LGALS9-HAVCR2 were frequently observed between myeloid cells, master cells, B cells and tumor cells (Figures 6C, D).